1 / 30

Opioid Selection for Acute and Chronic Pain Control

Opioid Selection for Acute and Chronic Pain Control. J K Lilly MD MS Appalachian Pain Therapy Institute Charleston, WV. Objectives. Identify the difference between acute and chronic pain treatment in opioid- naive verses opioid-tolerant patients.

Télécharger la présentation

Opioid Selection for Acute and Chronic Pain Control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. Opioid Selection for Acute and Chronic Pain Control J K Lilly MD MS Appalachian Pain Therapy Institute Charleston, WV

  2. Objectives • Identify the difference between acute and chronic pain treatment in opioid- naive verses opioid-tolerant patients. • Identify medications appropriate for treatment of each type of pain. • Know the EquianalgesicDoses of IV Morphine, Dilaudid and Fentanyl & convert to oral doses (enterohepatic=1.3). • Know about Iatrogenic Abstinence Syndrome • Realistically apply the Visual Analog Pain Score to evaluating response to opioids. • Differentiate Addiction Disorder from Chronic Pain and Chronic Pain Behavior

  3. Equianalgesic Dosing Pure Opioids

  4. Equianalgesic DosingWeak Opioids and Mixed AgonistsDrug PO IM & ½ Life

  5. Equianalgesic Dosing • Consider the example of switching from Methadone 10 tid to Oxycodone-SR • First, determine the Morphine equivalent dose to current drug, • Then, estimate dose of new drug from the Morphine equianalgesic dose i.e. Methadone → Morphine → Oxycodone 30 mg/d x 8 = 240 mg/d x .66=160mg/day

  6. Equianalgesic Dosing • Convert from Fentanyl 50 mcg/hr patch plus Percocet 10/650 up to tid for recurrent pain plus IV Demerol 25 mg up to once per shift for “bad” pain to IV Morphine infusion dose (real example) Fent 50 x24hr=1200 mcg/day x100= 120mg MS; Oxycod 30 x1.3= ~ 40mg MS; Demerol 75 = 75x.1= ~8-10mg MS => 120+~40+~10= ~180mgMS equivalentdose/day or IV-infusion hourly dose of 6.6 mg/hr

  7. Acute Pain Control Plan • Acute Pain: physical discomfort, short duration (hours to weeks), usually severe, usually associated with disease, birthing process or injury • Opioid-Naïve(narcotic celibacy) • Opioid-Tolerant (taking the equivalent of >25 mg/ day of Oxycodone or equivalent dose of any sustained release opioid preparation) • Visual Analog Pain Score (0-10) only advisory!

  8. Chronic Pain Control Plan • Pain lasting longer than six months • Persists disproportionately beyond the initial cause • May not respond in the same way as acute pain to techniques and medications • Cause may not be resolvable! • May require combined treatment modalities • Long Term Opioid Therapy (LTOT) may be the final therapeutic (last/ best) alternative • Chronic Pain Syndrome and its attendant behavior ARE NOT equivalent to Addiction Disorder

  9. Opioid -Naive With PCA (preferred) • Continuous (controversial)- MS 2mg/hr or second line drug in equianalgesic dose (0.2 mg/ hr HM, 20 mcg/ hr Fentanyl) • Demand Bolus - MS 1 mg or equianalgesic dose • Lockout – 10-15 minutes • Rescue– RN administered intermittent rescue ~ twice the dose of PCA bolus q 1 hr prn until reviewed • Review & adjust orders q 12 hrs • Continuous Oximetry

  10. Opioid -Naive Without PCA (but IV) • First Line: Morphine 2mg IV q 5 min prn ‘til comfortable or AE • Second Line: • Hydromorphone 0.2 mg IV q 5 min prn or Fentanyl 20 mcg IV q 5 min prn, (1st if creatanine >2.5) Meperidine not recommended!! • Review orders q 12 hrs • Continuous Oximetry • Convert to Oral ASAP • Avoid 3rd & 4th Line Agents

  11. Opioid Tolerant (taking opioid equivalent to >25 mg Oxycodone/ 24 hrs ) With PCA (preferred) Continuous Infusion = PCA Background – baseline 24 hr opioid dose X .3 per day, (ie. MS Contin 60mg q12h = 120 x .3 = 40mg/24hrs, or 2.5mg/ hr infusion – round-up to 3mg/ hr) PCA Demand- 50-100% of hourly rate, Lockout – q10-15 min Review adjust at least q 12h, titrate systematically Continuous Oximetry

  12. Opioid Tolerant(taking opioid equivalent to >25 mg Oxycodone/ 24 hrs ) Without PCA 10-20% of 24 hr dose q 1-3 hrs prn “basal dose” RN administered IV “Rescue Doses” @ 2x the “basal dose” Continuous Oximetry Adjust doses q 12h

  13. Pain Taxonomy • Acute Pain- tissue injury, distention or inflammation • Episodic Pain- related to activity recurrent, breakthrough, incident • Chronic Pain- constant and unremitting waxes & wanes but seldom subsides

  14. Episodic Pain • Short acting opioids indicated • Oral route preferred • Usually treated Schedule III (+APAP or IB) • Exertion/ Activity related

  15. Constant Pain • Sustained Response (SR) oral agents indicated • Consider Immediate Response (IR) agents for rescue doses – start at ~10% of 24 hr dose of long acting agent q4-8 hrs prn • SR formulations are designed for q 12 hr dosing but mean effective dose may be shorter duration (q 8-10 hr) • Use coanalagesics and anticipate adverse effects • Addiction risk is 3% or less (large studies)

  16. Analgesic Selection • Mu (m) Opioid Receptor Agonists – most familiar to clinicians as to effects and side-effects; best for initiating opioid therapy for moderate to severe pain (VAPS 5-10/10). • Morphine, Hydromorphone, Oxycodone, Hydrocodone, Fentanyl, Codeine, Hydrocodeine, Levorphanol, Methadone, Meperidine. .

  17. Analgesic Selection • Agonist/ Antagonists & Partial Agonists – Primarily activate the Kappa (k) receptor and antagonize or partially occupy the Mu receptor (m antagonists), analgesic ceiling effect, risk iatrogenic abstinence syndrome when given with m agonist tolerant patients, watch out in ER! no proven advantage in avoiding abuse. • Pentazocine, Butorphanol, Nalbuphine and the “partial agonists” Buprenorphine and Dezocine (VAPS 4-7/10)

  18. 3rd & 4th Line Analgesic Agents • Limited Proven Analgesic Efficacy • Adverse Effects • Drug-to-Drug Interaction • Toxic Metabolites • Organ-limited Elimination

  19. 3rd & 4th Line Analgesic Agents • Propoxyphene equianalgesic to Extra Strength Tylenol in blind studies (VAPS 1-3/10 = mild) norpropoxyphene-cardio & neurotoxic • Tramadol weak m agonist but primarily active on spinal adrenergic receptors similar to tricyclics (VAPS 4-5/10 = moderate) • Meperidine short acting (450-90 mins), metabolites accumulate within 48 hrs, side-effects common normeperidine- cardio & neurotoxic • Codiene effective pain relief but many side-effects at analgesic doses • Hydrocodiene isn’t routinely monitored on UDS • NSAIDs, APAP and AEDs, TCAD are “co-analgesics”

  20. Dosing for Relief • Around-The-Clock (ATC) dosing is associated with more consistent relief • PRN-dosing is associated with more unpredictability and side-effects • Optimal analgesic dosing varies widely among patients; review regularly; titrate systematically • Anticipate side effects; most subside with time • For some, NO dose of opioid will sufficiently relieve ALL of their pain...aim for TOLERABLE pain levels (VPA3-4/10), improved functionality and controlled side effect • Transition quickly from IV to PO (enterohepatic)

  21. Opioids and Addiction Physical Dependence • Physiologic occurrence usually within 3 days of initiating therapy; • Pharmacological property characterized by withdrawal syndrome after abrupt discontinuation; • Abstinence symptoms usually lacking or attenuated with “wean to discontinue” orders • NOT synonymous with tolerance or addiction!

  22. Opioids and Addiction Tolerance • Spectrum of acquired physiologic responses to therapy • Pharmacological property of the class drug; With chronic use, larger dose may be needed for same effect • Countered with drug rotations, furloughs, tolerance inhibitors, prescriptive boundaries • NOT synonymous with physical dependence or addiction!

  23. Opioids and Addiction Pseudo-addiction • Usually attributable to provider practice pattern, ergo iatrogenic • Unrealistic expectation by prescriber • Misconceived safety concern by providers • Patient motivation: ”relief, not rush” • NOT synonymous with physical dependence, tolerance or addiction!

  24. Opioids and Addiction Addiction • Psychological and physiologic state (<3 & >0.3% of chronic pain suffers) characterized by obsessive pursuit of access to medication- regardless of consequences, for psychologicaleffects • Not a pharmacological property of a given drug • NOT synonymous with tolerance or physical dependence!

  25. Plan if Addiction is Recognized -Be Humane -Intervene and Wean to withdrawal -Evaluation, treatment and extended recovery care by addiction professionals is optimal -Know community and regional resources for treatment & extended recovery care when initiating LTOT -Prescribing opioids to treat addiction (Methadone Clinics) is advisable only for specially certified addiction medicine and psychiatry physicians -Buprenorphine Addiction Treatment (Subtex) requires additional training and additional DEA certification…too new to assess.

  26. Opioid TherapyCurrent Clinical Guidelines • Pain relief is defined as a primary care (PCP) function • Remain reasonable, rational, responsible and available • Examine thoroughly and review regularly • Utilize LTOT Informed Consent to TreatandOpiate AccessAgreement • Document & define providers & pharmacy • Require patient to notify all providers of Opiate AccessAgreement participation • Monitorcompliance (pill counts, UDS, etc.) andresponse to therapy (functional assessments, charts, diaries, surveys, etc.), • Review OAA violation consequences regularly • Match the tool to the problem-SR opioid for continual pain, IR for recurrent pain; pick analgesics sensibly

  27. Opioid TherapyCurrent Clinical Guidelines (cont.) • Consult and co-manage appropriately, require formal behavioral assessment periodically • Stipulate that verified non-clinical information may be considered when deciding whether to continue LTOT • Beware of 90 day prescription “Prescription Drug Benefit Requirements” -cost saving scheme that may be technically illegal for opioids; i.e.. unmonitored and unlicensed warehousing of Class II & III medications in homes not supported by law or regulation • Recognize that LTOT may be the therapy oflast resort

  28. Opioid Options on the Near Horizon • Lipid-Based Sustained Release Opioid & Local Anesthetic Vehicles • Vanilloid and Cannabinoid Receptor Agonists • New Spinally-infused Drugs • Abuse-resistant Opioid Preparations • Co-analgesic Use of Anti-seizure Drugs • Deep-Brain and Motor Cortex Stimulation

  29. Thanks! IEnjoyed your attention!

  30. Opioid Selection for Acute and Chronic Pain Control Thanks for you’re your questions!! It’s time to head home.

More Related